Nucleic Acid Bioconjugates in Cancer Detection and Therapy
Nucleoside‐ and nucleotide‐based chemotherapeutics have been used to treat cancer for more than 50 years. However, their inherent cytotoxicities and the emergent resistance of tumors against treatment has inspired a new wave of compounds in which the overall pharmacological profile of the bioactive...
Gespeichert in:
Veröffentlicht in: | ChemMedChem 2016-02, Vol.11 (3), p.252-269 |
---|---|
Hauptverfasser: | , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 269 |
---|---|
container_issue | 3 |
container_start_page | 252 |
container_title | ChemMedChem |
container_volume | 11 |
creator | Patel, Pradeepkumar L. Rana, Niki K. Patel, Mayurbhai R. Kozuch, Stephen D. Sabatino, David |
description | Nucleoside‐ and nucleotide‐based chemotherapeutics have been used to treat cancer for more than 50 years. However, their inherent cytotoxicities and the emergent resistance of tumors against treatment has inspired a new wave of compounds in which the overall pharmacological profile of the bioactive nucleic acid component is improved by conjugation with delivery vectors, small‐molecule drugs, and/or imaging modalities. In this manner, nucleic acid bioconjugates have the potential for targeting and effecting multiple biological processes in tumors, leading to synergistic antitumor effects. Consequently, tumor resistance and recurrence is mitigated, leading to more effective forms of cancer therapy. Bioorthogonal chemistry has led to the development of new nucleoside bioconjugates, which have served to improve treatment efficacy en route towards FDA approval. Similarly, oligonucleotide bioconjugates have shown encouraging preclinical and clinical results. The modified oligonucleotides and their pharmaceutically active formulations have addressed many weaknesses of oligonucleotide‐based drugs. They have also paved the way for important advancements in cancer diagnosis and treatment. Cancer‐targeting ligands such as small‐molecules, peptides, and monoclonal antibody fragments have all been successfully applied in oligonucleotide bioconjugation and have shown promising anticancer effects in vitro and in vivo. Thus, the application of bioorthogonal chemistry will, in all likelihood, continue to supply a promising pipeline of nucleic acid bioconjugates for applications in cancer detection and therapy.
An anticancer firestorm! Recent advances in the design and development of modified nucleic acid bioconjugates and their formulation into biocompatible materials have enhanced their utility in cancer research. This review highlights selected classes of nucleic acid bioconjugates, discusses the methods behind their synthesis, and outlines their impact in cancer detection and therapy. |
doi_str_mv | 10.1002/cmdc.201500502 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1776650573</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1762686199</sourcerecordid><originalsourceid>FETCH-LOGICAL-c5802-1657baa63f16bd75c5a66e710b2e3bf2ca88feff835f5f4e54383381eae355803</originalsourceid><addsrcrecordid>eNqNkTtPwzAURi0E4r0yokgsLCl2HD_CBgEKUnkMRYyW41yDS5oUOxH035OqUCEWmO4dznekez-EDggeEIyTEzMtzSDBhGHMcLKGtonkOBZEivXVLrIttBPCBOM0lURuoq2Ec05xxrbR6V1nKnAmOjOujM5dY5p60j3rFkLk6ijXtQEfXUALpnVNHem6jMYv4PVsvoc2rK4C7H_NXfR4dTnOr-PR_fAmPxvFhkmcxIQzUWjNqSW8KAUzTHMOguAiAVrYxGgpLVgrKbPMpsBSKimVBDRQ1hvoLjpeeme-eesgtGrqgoGq0jU0XVBECM4ZZoL-A-UJl5xkWY8e_UInTefr_pAF1f8szTLeU4MlZXwTggerZt5NtZ8rgtWiALUoQK0K6AOHX9qumEK5wr8_3gPZEnh3Fcz_0Kn89iL_KY-XWRda-FhltX9VXFDB1NPdUI1HTAzTq5F6oJ_3wZ4x</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1761794996</pqid></control><display><type>article</type><title>Nucleic Acid Bioconjugates in Cancer Detection and Therapy</title><source>MEDLINE</source><source>Access via Wiley Online Library</source><creator>Patel, Pradeepkumar L. ; Rana, Niki K. ; Patel, Mayurbhai R. ; Kozuch, Stephen D. ; Sabatino, David</creator><creatorcontrib>Patel, Pradeepkumar L. ; Rana, Niki K. ; Patel, Mayurbhai R. ; Kozuch, Stephen D. ; Sabatino, David</creatorcontrib><description>Nucleoside‐ and nucleotide‐based chemotherapeutics have been used to treat cancer for more than 50 years. However, their inherent cytotoxicities and the emergent resistance of tumors against treatment has inspired a new wave of compounds in which the overall pharmacological profile of the bioactive nucleic acid component is improved by conjugation with delivery vectors, small‐molecule drugs, and/or imaging modalities. In this manner, nucleic acid bioconjugates have the potential for targeting and effecting multiple biological processes in tumors, leading to synergistic antitumor effects. Consequently, tumor resistance and recurrence is mitigated, leading to more effective forms of cancer therapy. Bioorthogonal chemistry has led to the development of new nucleoside bioconjugates, which have served to improve treatment efficacy en route towards FDA approval. Similarly, oligonucleotide bioconjugates have shown encouraging preclinical and clinical results. The modified oligonucleotides and their pharmaceutically active formulations have addressed many weaknesses of oligonucleotide‐based drugs. They have also paved the way for important advancements in cancer diagnosis and treatment. Cancer‐targeting ligands such as small‐molecules, peptides, and monoclonal antibody fragments have all been successfully applied in oligonucleotide bioconjugation and have shown promising anticancer effects in vitro and in vivo. Thus, the application of bioorthogonal chemistry will, in all likelihood, continue to supply a promising pipeline of nucleic acid bioconjugates for applications in cancer detection and therapy.
An anticancer firestorm! Recent advances in the design and development of modified nucleic acid bioconjugates and their formulation into biocompatible materials have enhanced their utility in cancer research. This review highlights selected classes of nucleic acid bioconjugates, discusses the methods behind their synthesis, and outlines their impact in cancer detection and therapy.</description><identifier>ISSN: 1860-7179</identifier><identifier>EISSN: 1860-7187</identifier><identifier>DOI: 10.1002/cmdc.201500502</identifier><identifier>PMID: 26663095</identifier><language>eng</language><publisher>Germany: Blackwell Publishing Ltd</publisher><subject>Acids ; Antibodies, Monoclonal - chemistry ; Antibodies, Monoclonal - therapeutic use ; anticancer agents ; Antineoplastic Agents - chemistry ; Antineoplastic Agents - therapeutic use ; bioconjugation ; bioorthogonal chemistry ; Cancer ; Cancer therapies ; Humans ; Neoplasms - diagnosis ; Neoplasms - drug therapy ; nucleic acids ; Nucleic Acids - chemistry ; Nucleic Acids - therapeutic use ; Oligonucleotides - chemistry ; Oligonucleotides - therapeutic use ; Peptides - chemistry ; Peptides - therapeutic use ; Small Molecule Libraries - chemistry ; Small Molecule Libraries - therapeutic use ; Tumors</subject><ispartof>ChemMedChem, 2016-02, Vol.11 (3), p.252-269</ispartof><rights>2016 WILEY‐VCH Verlag GmbH & Co. KGaA, Weinheim</rights><rights>2016 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.</rights><rights>2016 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c5802-1657baa63f16bd75c5a66e710b2e3bf2ca88feff835f5f4e54383381eae355803</citedby><cites>FETCH-LOGICAL-c5802-1657baa63f16bd75c5a66e710b2e3bf2ca88feff835f5f4e54383381eae355803</cites><orcidid>0000-0002-9797-0833</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fcmdc.201500502$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fcmdc.201500502$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,27924,27925,45574,45575</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26663095$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Patel, Pradeepkumar L.</creatorcontrib><creatorcontrib>Rana, Niki K.</creatorcontrib><creatorcontrib>Patel, Mayurbhai R.</creatorcontrib><creatorcontrib>Kozuch, Stephen D.</creatorcontrib><creatorcontrib>Sabatino, David</creatorcontrib><title>Nucleic Acid Bioconjugates in Cancer Detection and Therapy</title><title>ChemMedChem</title><addtitle>ChemMedChem</addtitle><description>Nucleoside‐ and nucleotide‐based chemotherapeutics have been used to treat cancer for more than 50 years. However, their inherent cytotoxicities and the emergent resistance of tumors against treatment has inspired a new wave of compounds in which the overall pharmacological profile of the bioactive nucleic acid component is improved by conjugation with delivery vectors, small‐molecule drugs, and/or imaging modalities. In this manner, nucleic acid bioconjugates have the potential for targeting and effecting multiple biological processes in tumors, leading to synergistic antitumor effects. Consequently, tumor resistance and recurrence is mitigated, leading to more effective forms of cancer therapy. Bioorthogonal chemistry has led to the development of new nucleoside bioconjugates, which have served to improve treatment efficacy en route towards FDA approval. Similarly, oligonucleotide bioconjugates have shown encouraging preclinical and clinical results. The modified oligonucleotides and their pharmaceutically active formulations have addressed many weaknesses of oligonucleotide‐based drugs. They have also paved the way for important advancements in cancer diagnosis and treatment. Cancer‐targeting ligands such as small‐molecules, peptides, and monoclonal antibody fragments have all been successfully applied in oligonucleotide bioconjugation and have shown promising anticancer effects in vitro and in vivo. Thus, the application of bioorthogonal chemistry will, in all likelihood, continue to supply a promising pipeline of nucleic acid bioconjugates for applications in cancer detection and therapy.
An anticancer firestorm! Recent advances in the design and development of modified nucleic acid bioconjugates and their formulation into biocompatible materials have enhanced their utility in cancer research. This review highlights selected classes of nucleic acid bioconjugates, discusses the methods behind their synthesis, and outlines their impact in cancer detection and therapy.</description><subject>Acids</subject><subject>Antibodies, Monoclonal - chemistry</subject><subject>Antibodies, Monoclonal - therapeutic use</subject><subject>anticancer agents</subject><subject>Antineoplastic Agents - chemistry</subject><subject>Antineoplastic Agents - therapeutic use</subject><subject>bioconjugation</subject><subject>bioorthogonal chemistry</subject><subject>Cancer</subject><subject>Cancer therapies</subject><subject>Humans</subject><subject>Neoplasms - diagnosis</subject><subject>Neoplasms - drug therapy</subject><subject>nucleic acids</subject><subject>Nucleic Acids - chemistry</subject><subject>Nucleic Acids - therapeutic use</subject><subject>Oligonucleotides - chemistry</subject><subject>Oligonucleotides - therapeutic use</subject><subject>Peptides - chemistry</subject><subject>Peptides - therapeutic use</subject><subject>Small Molecule Libraries - chemistry</subject><subject>Small Molecule Libraries - therapeutic use</subject><subject>Tumors</subject><issn>1860-7179</issn><issn>1860-7187</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkTtPwzAURi0E4r0yokgsLCl2HD_CBgEKUnkMRYyW41yDS5oUOxH035OqUCEWmO4dznekez-EDggeEIyTEzMtzSDBhGHMcLKGtonkOBZEivXVLrIttBPCBOM0lURuoq2Ec05xxrbR6V1nKnAmOjOujM5dY5p60j3rFkLk6ijXtQEfXUALpnVNHem6jMYv4PVsvoc2rK4C7H_NXfR4dTnOr-PR_fAmPxvFhkmcxIQzUWjNqSW8KAUzTHMOguAiAVrYxGgpLVgrKbPMpsBSKimVBDRQ1hvoLjpeeme-eesgtGrqgoGq0jU0XVBECM4ZZoL-A-UJl5xkWY8e_UInTefr_pAF1f8szTLeU4MlZXwTggerZt5NtZ8rgtWiALUoQK0K6AOHX9qumEK5wr8_3gPZEnh3Fcz_0Kn89iL_KY-XWRda-FhltX9VXFDB1NPdUI1HTAzTq5F6oJ_3wZ4x</recordid><startdate>20160204</startdate><enddate>20160204</enddate><creator>Patel, Pradeepkumar L.</creator><creator>Rana, Niki K.</creator><creator>Patel, Mayurbhai R.</creator><creator>Kozuch, Stephen D.</creator><creator>Sabatino, David</creator><general>Blackwell Publishing Ltd</general><general>Wiley Subscription Services, Inc</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QO</scope><scope>7TK</scope><scope>7U7</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>K9.</scope><scope>P64</scope><scope>RC3</scope><scope>7X8</scope><scope>7TM</scope><orcidid>https://orcid.org/0000-0002-9797-0833</orcidid></search><sort><creationdate>20160204</creationdate><title>Nucleic Acid Bioconjugates in Cancer Detection and Therapy</title><author>Patel, Pradeepkumar L. ; Rana, Niki K. ; Patel, Mayurbhai R. ; Kozuch, Stephen D. ; Sabatino, David</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c5802-1657baa63f16bd75c5a66e710b2e3bf2ca88feff835f5f4e54383381eae355803</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Acids</topic><topic>Antibodies, Monoclonal - chemistry</topic><topic>Antibodies, Monoclonal - therapeutic use</topic><topic>anticancer agents</topic><topic>Antineoplastic Agents - chemistry</topic><topic>Antineoplastic Agents - therapeutic use</topic><topic>bioconjugation</topic><topic>bioorthogonal chemistry</topic><topic>Cancer</topic><topic>Cancer therapies</topic><topic>Humans</topic><topic>Neoplasms - diagnosis</topic><topic>Neoplasms - drug therapy</topic><topic>nucleic acids</topic><topic>Nucleic Acids - chemistry</topic><topic>Nucleic Acids - therapeutic use</topic><topic>Oligonucleotides - chemistry</topic><topic>Oligonucleotides - therapeutic use</topic><topic>Peptides - chemistry</topic><topic>Peptides - therapeutic use</topic><topic>Small Molecule Libraries - chemistry</topic><topic>Small Molecule Libraries - therapeutic use</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Patel, Pradeepkumar L.</creatorcontrib><creatorcontrib>Rana, Niki K.</creatorcontrib><creatorcontrib>Patel, Mayurbhai R.</creatorcontrib><creatorcontrib>Kozuch, Stephen D.</creatorcontrib><creatorcontrib>Sabatino, David</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Biotechnology Research Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><collection>Nucleic Acids Abstracts</collection><jtitle>ChemMedChem</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Patel, Pradeepkumar L.</au><au>Rana, Niki K.</au><au>Patel, Mayurbhai R.</au><au>Kozuch, Stephen D.</au><au>Sabatino, David</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Nucleic Acid Bioconjugates in Cancer Detection and Therapy</atitle><jtitle>ChemMedChem</jtitle><addtitle>ChemMedChem</addtitle><date>2016-02-04</date><risdate>2016</risdate><volume>11</volume><issue>3</issue><spage>252</spage><epage>269</epage><pages>252-269</pages><issn>1860-7179</issn><eissn>1860-7187</eissn><abstract>Nucleoside‐ and nucleotide‐based chemotherapeutics have been used to treat cancer for more than 50 years. However, their inherent cytotoxicities and the emergent resistance of tumors against treatment has inspired a new wave of compounds in which the overall pharmacological profile of the bioactive nucleic acid component is improved by conjugation with delivery vectors, small‐molecule drugs, and/or imaging modalities. In this manner, nucleic acid bioconjugates have the potential for targeting and effecting multiple biological processes in tumors, leading to synergistic antitumor effects. Consequently, tumor resistance and recurrence is mitigated, leading to more effective forms of cancer therapy. Bioorthogonal chemistry has led to the development of new nucleoside bioconjugates, which have served to improve treatment efficacy en route towards FDA approval. Similarly, oligonucleotide bioconjugates have shown encouraging preclinical and clinical results. The modified oligonucleotides and their pharmaceutically active formulations have addressed many weaknesses of oligonucleotide‐based drugs. They have also paved the way for important advancements in cancer diagnosis and treatment. Cancer‐targeting ligands such as small‐molecules, peptides, and monoclonal antibody fragments have all been successfully applied in oligonucleotide bioconjugation and have shown promising anticancer effects in vitro and in vivo. Thus, the application of bioorthogonal chemistry will, in all likelihood, continue to supply a promising pipeline of nucleic acid bioconjugates for applications in cancer detection and therapy.
An anticancer firestorm! Recent advances in the design and development of modified nucleic acid bioconjugates and their formulation into biocompatible materials have enhanced their utility in cancer research. This review highlights selected classes of nucleic acid bioconjugates, discusses the methods behind their synthesis, and outlines their impact in cancer detection and therapy.</abstract><cop>Germany</cop><pub>Blackwell Publishing Ltd</pub><pmid>26663095</pmid><doi>10.1002/cmdc.201500502</doi><tpages>18</tpages><orcidid>https://orcid.org/0000-0002-9797-0833</orcidid></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1860-7179 |
ispartof | ChemMedChem, 2016-02, Vol.11 (3), p.252-269 |
issn | 1860-7179 1860-7187 |
language | eng |
recordid | cdi_proquest_miscellaneous_1776650573 |
source | MEDLINE; Access via Wiley Online Library |
subjects | Acids Antibodies, Monoclonal - chemistry Antibodies, Monoclonal - therapeutic use anticancer agents Antineoplastic Agents - chemistry Antineoplastic Agents - therapeutic use bioconjugation bioorthogonal chemistry Cancer Cancer therapies Humans Neoplasms - diagnosis Neoplasms - drug therapy nucleic acids Nucleic Acids - chemistry Nucleic Acids - therapeutic use Oligonucleotides - chemistry Oligonucleotides - therapeutic use Peptides - chemistry Peptides - therapeutic use Small Molecule Libraries - chemistry Small Molecule Libraries - therapeutic use Tumors |
title | Nucleic Acid Bioconjugates in Cancer Detection and Therapy |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-23T07%3A15%3A04IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Nucleic%20Acid%20Bioconjugates%20in%20Cancer%20Detection%20and%20Therapy&rft.jtitle=ChemMedChem&rft.au=Patel,%20Pradeepkumar%20L.&rft.date=2016-02-04&rft.volume=11&rft.issue=3&rft.spage=252&rft.epage=269&rft.pages=252-269&rft.issn=1860-7179&rft.eissn=1860-7187&rft_id=info:doi/10.1002/cmdc.201500502&rft_dat=%3Cproquest_cross%3E1762686199%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1761794996&rft_id=info:pmid/26663095&rfr_iscdi=true |